NeuroBo Pharmaceuticals: Clinical stage biotechnology company NeuroBo Pharmaceuticals NRBO -16.3% + Free Alerts tops the short squeeze leaderboard for the week of Sept. 19. The company has 36.9% of its float short and a cost to borrow of 148.9%, ranking among the highest for both key factors that can determine how likely a short squeeze is to happen.